Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Glucagon-like peptide-1 receptor agonists and diabetic retinopathy: nationwide cohort and Mendelian randomization studies

Open access

Abstract

Background: The ability of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) to decrease certain microvascular events has called for the investigation of GLP-1 RAs against diabetic retinopathy (DR), but the evidence is limited. By combining data from observational and Mendelian randomization (MR) studies, we aimed to investigate whether GLP-1 RAs decrease the risk of DR. Methods: We combined data from several Swedish Registers and identified patients with incident type 2 diabetes being treated with GLP-1 RAs between 2006 and 2015, and matched them to diabetic patients who did not use GLP-1 RAs as the comparisons. The Cox proportional hazards models were applied to assess the risk of DR. We further performed the summary-data-based MR (SMR) analyses based on the Genotype-Tissue Expression databases and the Genome-Wide Association Study of DR from the FinnGen consortium. Results: A total of 2390 diabetic patients were treated with GLP-1 RAs and the incidence of DR was 5.97 per 1000 person-years. Compared with diabetic patients who did not use GLP-1 RAs having an incidence of 12.85 per 1000 person-years, the adjusted hazard ratio (HR) of DR was 0.42 [95% confidence interval (CI), 0.29–0.61]. Genetically-predicted GLP1R expression (the target of GLP-1 RAs) showed an inverse association with background [odds ratio (OR)=0.83, 95% CI, 0.71–0.97] and severe nonproliferative DR (OR=0.72, 95% CI, 0.53–0.98), and a non-significant association with overall (OR=0.97, 95% CI, 0.92–1.03) and proliferative DR (OR=0.98, 95% CI, 0.91–1.05). Conclusions: Both observational and mendelian randomization analyses showed a significantly lower risk of DR for patients treated with GLP-1 RAs, which calls for further studies to validate these findings.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12916-023-02753-6

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Identification of eligible patients and development of cohorts in the study and the design of summary-data-based Mendelian randomization (SMR) model. A Identification of eligible patients and development of cohorts in the observational study. GLP-1 RAs, Glucagon-like peptide-1 receptor agonists; DDD, Defined daily dose. B The design of summary-data-based Mendelian randomization (SMR) model. ×: there are no associations between genetic variants and exposure (or outcome). GWAS, Genome-Wide Association Study; eQTL, Expression quantitative trait loci; SMR, Summary-data-based Mendelian randomization; SNP, Single nucleotide polymorphism; MAF, Minor allele frequency
Fig. 1 Identification of eligible patients and development of cohorts in the study and the design of summary-data-based Mendelian randomization (SMR) model. A Identification of eligible patients and development of cohorts in the observational study. GLP-1 RAs, Glucagon-like peptide-1 receptor agonists; DDD, Defined daily dose. B The design of summary-data-based Mendelian randomization (SMR) model. ×: there are no associations between genetic variants and exposure (or outcome). GWAS, Genome-Wide Association Study; eQTL, Expression quantitative trait loci; SMR, Summary-data-based Mendelian randomization; SNP, Single nucleotide polymorphism; MAF, Minor allele frequencyCC BY · PubMed Central
Fig. 2 Cumulative incidence estimates (Kaplan-Meier) for DR and the forest plot about the association between GLP-1 RAs and DR using Cox regression. DR, Diabetic retinopathy; GLP-1 RAs, Glucagon-like peptide-1 receptor agonists. A Cumulative incidence estimates (Kaplan-Meier) for DR in non-GLP-1 RAs and GLP-1 RAs groups. The blue and red lines indicate the cumulative incidence rate of the non-GLP-1 RAs group and the GLP-1 RAs group, separately. DR, Diabetic retinopathy; GLP-1 RAs, Glucagon-like peptide-1 receptor agonists. B The forest plot about the association between GLP-1 RAs and DR using Cox regression for four models. The association between GLP-1 RAs and DR was significant in all models. HR, Hazard ratio; CI, Confidence interval; GLP-1 RAs, Glucagon-like peptide-1 receptor agonists; DR, Diabetic retinopathy
Fig. 2 Cumulative incidence estimates (Kaplan-Meier) for DR and the forest plot about the association between GLP-1 RAs and DR using Cox regression. DR, Diabetic retinopathy; GLP-1 RAs, Glucagon-like peptide-1 receptor agonists. A Cumulative incidence estimates (Kaplan-Meier) for DR in non-GLP-1 RAs and GLP-1 RAs groups. The blue and red lines indicate the cumulative incidence rate of the non-GLP-1 RAs group and the GLP-1 RAs group, separately. DR, Diabetic retinopathy; GLP-1 RAs, Glucagon-like peptide-1 receptor agonists. B The forest plot about the association between GLP-1 RAs and DR using Cox regression for four models. The association between GLP-1 RAs and DR was significant in all models. HR, Hazard ratio; CI, Confidence interval; GLP-1 RAs, Glucagon-like peptide-1 receptor agonists; DR, Diabetic retinopathyCC BY · PubMed Central
Fig. 3 Association of GLP-1 RAs and DR using Cox regression in the sensitivity and subgroup analyses. The treatment of GLP-1 RAs was also associated with the risk of DR after excluding the patients with less than 6 months of follow-up. Subgroup analyses indicated GLP-1 RAs were associated with DR in men but not in women. GLP-1 RAs, Glucagon-like peptide-1 receptor agonists; HR, Hazard ratio; CI, Confidence interval; DR, Diabetic retinopathy
Fig. 3 Association of GLP-1 RAs and DR using Cox regression in the sensitivity and subgroup analyses. The treatment of GLP-1 RAs was also associated with the risk of DR after excluding the patients with less than 6 months of follow-up. Subgroup analyses indicated GLP-1 RAs were associated with DR in men but not in women. GLP-1 RAs, Glucagon-like peptide-1 receptor agonists; HR, Hazard ratio; CI, Confidence interval; DR, Diabetic retinopathyCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 35 references

Cited by

See all 74

Metadata

Authors
Zheng, D., Li, N., Hou, R., Zhang, X., Wu, L., Sundquist, J., Sundquist, K., & Ji, J.
Affiliations
  • Capital Medical University (CN)
  • Shimane University (JP)
  • Lund University (SE)
Corresponding author
  • Zhang, Xiaoyu
  • Ji, Jianguang
Venue
BMC Medicine
Published
2023-02-03
Volume
21
Issue
1
Pages
40-40
ISSN
1741-7015 (ISSN-L)
OpenAlex
W4319078643
Cited by
74
References
35
Citations by year
2026: 25 · 2025: 23 · 2024: 17 · 2023: 9
FWCI
15.09
Type
journal article
Language
en
Open access
Licence
Locations
  • BMC Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Lund University Publications (Lund University) (submittedVersion)
Funders
Lund University
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
GLP-1 receptor agonists, diabetic retinopathy, type 2 diabetes, non-proliferative diabetic retinopathy, proliferative diabetic retinopathy, microvascular complications
MeSH terms
Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Diabetic Retinopathy, Humans, Hypoglycemic Agents, Glucagon-Like Peptide 1, Genome-Wide Association Study, Mendelian Randomization Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glucagon-like peptide-1 receptor agonists and diabetic retinopathy: nationwide cohort and Mendelian randomization studies. https://app.cochat.ai/papers/10.1186/s12916-023-02753-6
The paper
Zheng, D., Li, N., Hou, R., Zhang, X., Wu, L., Sundquist, J., Sundquist, K., & Ji, J. (2023). Glucagon-like peptide-1 receptor agonists and diabetic retinopathy: nationwide cohort and Mendelian randomization studies. BMC Medicine. https://doi.org/10.1186/s12916-023-02753-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.